ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Bid For US Approval Of New Use For Humira Is Delayed

By Peter Loftus Of DOW JONES NEWSWIRES Abbott Laboratories (ABT) has encountered a delay in its bid for U.S. regulatory approval to expand the uses of its blockbuster anti-inflammatory drug Humira to include treatment of the bowel disease ulcerative colitis. Abbott received a "complete response letter" from the U.S. Food and Drug Administration in late 2011 regarding Abbott's application to market Humira for colitis, spokeswoman Elizabeth Hoff said Monday. The FDA sends such letters when a drug application isn't yet ready for approval. The Abbott Park, Ill., company has provided additional information and continues to have a dialogue with the FDA, Hoff said. Abbott expects an agency decision by the end of this year, she said. She declined to provide contents of the complete response letter. Abbott filed for regulatory approval of Humira to treat ulcerative colitis in the U.S. and Europe in early 2011. The European Commission approved the new use in April. The regulatory applications were based on clinical data showing that Humira improved rates of disease remission versus a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Humira is currently approved in the U.S. to treat rheumatoid arthritis and several other inflammatory conditions. Abbott recorded $7.9 billion in Humira sales for 2011. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stock News for Abbott Labs (ABT)
DateTimeHeadline
03/22/201714:47:13Current Report Filing (8-k)
03/22/201709:00:00Abbott Hosts Conference Call for First-Quarter Earnings
03/21/201706:01:32Notice of Effectiveness (effect)
03/20/201716:57:02Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
03/19/201714:00:00Late-Breaking Data Shows the CardioMEMS HF System is Effective...
03/18/201712:30:00Late-Breaking Data on Abbott's MitraClip® System Show Continued...
03/17/201717:04:39Statement of Changes in Beneficial Ownership (4)
03/17/201707:31:39Proxy Statement (definitive) (def 14a)
03/14/201712:25:53Current Report Filing (8-k)
03/08/201716:15:00Abbott to Present at Barclays Capital 2017 Global Healthcare...
03/08/201709:00:00New Study Results May Lead to a New Standard of Care for In Vitro...
03/07/201717:14:25Registration Statement for Securities to Be Issued in Business...
03/07/201709:00:00Abbott Announces Results of Early Tenders and Consents in Exchange...
03/02/201717:21:19Statement of Changes in Beneficial Ownership (4)
03/02/201717:21:19Statement of Changes in Beneficial Ownership (4)
03/02/201717:19:29Statement of Changes in Beneficial Ownership (4)
03/02/201717:17:53Statement of Changes in Beneficial Ownership (4)
03/02/201717:17:25Statement of Changes in Beneficial Ownership (4)
03/02/201717:16:36Statement of Changes in Beneficial Ownership (4)
03/02/201717:16:08Statement of Changes in Beneficial Ownership (4)

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US